Cerberus Therapeutics develops immunological solutions utilizing alpaca-derived single domain antibody fragments (VHH) to modulate the immune system. Their platform technologies focus on inducing antigen-specific tolerance and addressing infectious diseases. This approach aims to re-engineer the immune system by engaging its complex network rather than solely suppressing responses.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immunotherapies often rely on broad immune suppression or targeting specific pathogen regions, which can lead to significant side effects and limited long-term efficacy. There is a need for therapies that enable the immune system to self-regulate in an antigen-specific manner, promoting tolerance and effective responses without systemic suppression.
Solution
Cerberus Therapeutics is developing a platform of nanobody-based therapeutics derived from alpaca single-domain antibody fragments (VHHs) designed to modulate the immune system. Their approach aims to re-engineer the immune system, enabling it to self-regulate for antigen-specific tolerance and effective responses to infectious diseases. Unlike traditional methods, Cerberus's technology leverages the immune system's complex network to promote self-rewiring, leading to safer and more accessible therapies. This allows for targeted immune modulation without the broad immunosuppression associated with conventional treatments.
Target Audience
The primary target audience includes patients with autoimmune diseases and infectious diseases, as well as researchers and clinicians seeking novel immunomodulatory therapies.
Features
- Utilizes alpaca-derived single-domain antibody fragments (VHHs) for targeted immune modulation.
- Develops distinct platform technologies for antigen-specific tolerance.
- Creates innovative immunological solutions for infectious diseases.
- Promotes immune system self-regulation rather than broad suppression.